Core Viewpoint - Arch Biopartners Inc. has received ethics approval for St. Michael's Hospital to participate in a Phase II trial evaluating LSALT peptide for preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI) [1][2]. Company Overview - Arch Biopartners Inc. is a therapeutic biotech company focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney diseases (CKD) [16]. - The company is advancing an integrated program targeting inflammation- and toxin-related kidney injury, with LSALT peptide as its lead drug candidate [16]. Clinical Trial Details - The CS-AKI Phase II trial is an international, multi-center, randomized, double-blind, placebo-controlled study with a recruitment target of 240 patients [5]. - Patients will be randomized to receive either LSALT peptide (10mg IV twice daily for five days) or placebo, with the primary objective being to evaluate the percentage of subjects with acute kidney injury within seven days following on-pump cardiac surgery [5][6]. Research and Development - The trial aims to address a significant unmet medical need, as up to 30% of patients undergoing on-pump cardiac surgery develop CS-AKI, which can lead to serious complications and increased mortality [11]. - LSALT peptide works by binding to the dipeptidase-1 (DPEP1) enzyme, inhibiting its role in triggering organ inflammation, and has shown promise in pre-clinical models for preventing ischemia-reperfusion injury to the kidneys [8][7]. Collaboration and Site Activation - St. Michael's Hospital will be the ninth site activated globally and the fourth within a leading Canadian academic hospital network [2]. - Other active sites include Toronto General Hospital and the University of Calgary, with additional sites being evaluated in Canada and the United States [4].

Financial Data and Key Metrics Changes - The company reported a fourfold increase in net revenue for the first quarter of 2025, achieving $293,000 compared to approximately $68,000 in the fourth quarter of 2024 and $0 in the first quarter of the previous year [31][34] - The net loss for the first quarter of 2025 declined to $3,700,000 compared to a loss of $12,700,000 in the first quarter of 2024 [34] Business Line Data and Key Metrics Changes - The Quellimmune therapy saw increased adoption, driving revenue growth, with all existing customers purchasing the therapy during the quarter [31][32] - The company anticipates a total annual U.S. market opportunity of approximately $100,000,000 based on a pediatric AKI population of about 4,000 patients [14] Market Data and Key Metrics Changes - The adult AKI market represents a significant opportunity with over 200,000 adults affected, translating to a total annual market opportunity of about $4,500,000,000 in the U.S. [9][18] - The company is focusing on the top 50 pediatric sites in the U.S. for Quellimmune therapy adoption, with a strong interest from these institutions [15][16] Company Strategy and Development Direction - The primary goal for 2025 is to grow the customer base for Quellimmune therapy and complete the neutralized AKI pivotal trial [5][11] - The company aims to file a PMA for the adult AKI indication in 2026, contingent on positive trial results [27][37] - The strategic goal includes expanding the addressable market to target other critical unmet medical needs for treating destructive hyperinflammation [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future opportunities for SeaStar Medical, highlighting the potential to capture a significant portion of the adult AKI market [37] - The company is focused on maintaining careful attention to spending while pushing forward with its commercial launch and clinical trials [30][34] Other Important Information - The neutralized AKI trial has reached the 50% enrollment milestone, triggering an interim analysis by the independent Data Safety Monitoring Board [10][21] - The company has received breakthrough device designations for five other indications, indicating a robust pipeline for future growth [28] Q&A Session Summary Question: How many sites are currently activated for the adult clinical trial? - The company currently has 15 activated sites and plans to activate another five over the next three months [39] Question: What's the total number of pediatric hospitals that you have as customers currently? - The company has six commercially active sites and multiple others moving through the IRB process [41] Question: What sort of pipeline growth have you seen in the first quarter compared to the fourth quarter? - The growth is attributed to the experience of existing sites and word-of-mouth, with hospitals actively engaging in adopting Quellimmune therapy [42][44] Question: How important are the two additional breakthrough designations? - The company views cardiac surgery as a significant opportunity and plans to pursue additional clinical trials funded by grants and investigator-initiated studies [48][51]